



SCIENCE AND POLICY A PARTNERSHIP AGAINST AMR

ANTÓNIO CORREIA DE CAMPOS
MEMBER



**GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE**



Antibiotics
Antivirals
Antifungals
Antiparasitics

A SILENT PANDEMIC



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics

AMR- GLOBAL BURDEN

- 1.3 MILLION DEATHS ATTRIBUTED
- 3.7 MILLION ASSOCIATED DEATHS
- 294 COUNTRIES AND TERRITORIES
- THE THIRD LEADING UNDERLYING CAUSE OF DEATH, FOLLOWING ISCHEMIC HEART DISEASE AND STROKE
- GREATER IMPACT ON LICs and LMICs



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics

IMPACT IN LOW INCOME SETTINGS

- SUB-SAHARAN AFRICA WITH THE HIGHEST BURDEN OF AMR
- AFFECTS DISPROPORTIONATELY YOUNG CHILDREN: 1 IN 5 DEATHS
- HIGH NUMBER OF DEATHS FROM VACCINE PREVENTABLE BACTERIAL DISEASE (S. PNEUMONIAE)



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics

ANTIMICROBIAL RESISTANCE

- S. AUREUS, E. COLI, K. PNEUMONIAE, S. PNEUMONIAE, A. BAUMANNII, M. TUBERCULOSIS AND P. AERUGINOSA, MORE THAN 80,000 DEATHS/YEAR RELATED TO EACH ONE
- VACCINES ONLY AVAILABLE FOR TWO OF THESE



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics

- WHO
- FAO
- WAHO
- UNEP

FOUR U.N. AGENCIES ESTABLISHED A GLG/AMR



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics

LACK OF ACTION SCENARIO

- **GLOBALLY, AN AVERAGE LOSS OF 1.8 IN LIFE EXPECTANCY BY 2035**
- **AT THE CURRENT LEVEL OF ACTION, SOME LMICS WILL SEE THEIR AVERAGE LIFE EXPECTANCY DECREASE BY 2.5 DURING THIS PERIOD**



**GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE**



Antibiotics
Antivirals
Antifungals
Antiparasitics

ANNUAL ECONOMIC IMPACT UP TO 2035

- INCREASE IN HEALTHCARE EXPENDITURES
- \$412 BILLION ALLOCATED EXCLUSIVELY FOR THE TREATMENT OF INFECTIONS CAUSED BY RESISTANT BACTERIA
- LOSS OF WORKFORCE PRODUCTIVITY REACHING \$443 BILLION



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics

SETTING EVIDENCE



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics

➤ AMONG OTHER FACTORS, EVIDENCE RELIES ON:

***INFORMATION**

***INFERENCIES ACCURACY**

***PUBLICATION (PEER REVIEW, JOURNAL REPUTATION, REACTIONS)**

***REPLICABILITY**

***TEAM REPUTATION**

EVIDENCE RELIES ON



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics

➤ **POLITICAL DECISION DEPENDS ON:**

- * MAGNITUDE AND PERCEPTION OF THE PROBLEM**
- * EDUCATION AND SENSITIVITY OF DECISION-MAKERS**
- * POLITICAL PRIORITIES**
- * TIMING**
- * RESOURCES: HUMAN, FINANCIAL, ORGANIZATIONAL, AND LOGISTICAL**
- * DETERRENTS AND ENCOURAGERS**
- * ACTOR'S CULTURE AND PREJUDICES**
- * CAPACITY AND QUALITY OF IMPLEMENTATION**



**GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE**



Antibiotics
Antivirals
Antifungals
Antiparasitics

EXISTING:

- PROBLEM
MAGNITUDE
- RESOURCES
- SCIENTIFIC
KNOWLEDGE
- DINAMICS

LACKING:

- COMPLETE INFORMATION
ON EPI SURVEILLANCE
- INFORMED POLITICAL
DECISION MAKERS
- DIRECT CONTACT WITH
THE PROBLEM
- PRIORITY AWARENESS

THE AMR CASE



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics

- COVID-19 EXPERIENCE, SUCCESSES ANG FAILURES
- RUNNING OUT OF ABX PIPELINE
- PROBLEM MAGNITUDE GROWING UP
- GLOBAL INITIATIVE

AMR OPORTUNITIES



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics



GLOBAL LEADERS GROUP ON
ANTIMICROBIAL RESISTANCE

OBRIGADO | THANK YOU

GLOBAL LEADERS GROUP ON ANTIMICROBIAL RESISTANCE

<https://www.amrleaders.org/>



GLOBAL LEADERS GROUP
ON ANTIMICROBIAL RESISTANCE



Antibiotics
Antivirals
Antifungals
Antiparasitics